Yayın:
Plasma Thiol Levels are Associated with Disease Severity in Nonsegmental Vitiligo

dc.contributor.authorGulsen Akoglu
dc.contributor.authorSalim Neselioglu
dc.contributor.authorEda Karaismailoglu
dc.contributor.authorAkin Aktas
dc.contributor.authorOzcan Erel
dc.date.accessioned2026-01-03T10:42:24Z
dc.date.issued2018-07-01
dc.description.abstractBackground: Vitiligo is a depigmenting cutaneous disorder with complex pathogenesis. Thiol compounds are well-known organic structures that play a major role in melanogenesis. Aim: The aim of this study was to determine the association between plasma thiol level and disease severity in patients with nonsegmental vitiligo. Methods: A total of 73 patients with nonsegmental vitiligo (57 generalized and 16 localized type) and age- and sex-matched 69 healthy controls were enrolled in the study. Plasma levels of native thiols, disulfides, and total thiols were measured by a novel and automated assay. Disease severity of vitiligo was assessed with Vitiligo Area Scoring Index (VASI) score. The extent, stage, and spread of vitiligo of patients were evaluated according to the Vitiligo European Task Force (VETF) system. Results: The native and total thiol levels of vitiligo patients were higher than those of healthy control group (P≤0.001 and 0.001, respectively). The median VASI score of patients was 0.7 (0.02–28.30). Univariate analyses showed that plasma native thiol levels, VETF spread score, disease duration, and vitiligo type significantly correlated with VASI scores (r=0.237, P=0.043; r=0.458, P<0.001; and P<0.001, respectively). Stepwise multivariate analysis revealed that disease duration (β=0.017; P=0.005) and spread score (β=1.301; P=0.001) were found statistically significant as independent factors on VASI score. Conclusion: Although plasma native thiol level significantly correlated with VASI scores of patients, it is not a predictive factor for vitiligo severity.
dc.description.urihttps://doi.org/10.4103/ijd.ijd_586_17
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/30078877
dc.description.urihttp://dx.doi.org/10.4103/ijd.IJD_586_17
dc.description.urihttps://doaj.org/article/f33f38d96e434a0b8daa105398c61c99
dc.description.urihttps://dx.doi.org/10.4103/ijd.ijd_586_17
dc.identifier.doi10.4103/ijd.ijd_586_17
dc.identifier.eissn1998-3611
dc.identifier.endpage327
dc.identifier.issn0019-5154
dc.identifier.openairedoi_dedup___::71058830aae6e28ff2796997c19ba64c
dc.identifier.orcid0000-0002-0974-5717
dc.identifier.orcid0000-0003-3085-7809
dc.identifier.pubmed30078877
dc.identifier.scopus2-s2.0-85050069585
dc.identifier.startpage323
dc.identifier.urihttps://hdl.handle.net/20.500.12597/36900
dc.identifier.volume63
dc.identifier.wos000438987700009
dc.language.isoeng
dc.publisherOvid Technologies (Wolters Kluwer Health)
dc.relation.ispartofIndian Journal of Dermatology
dc.rightsOPEN
dc.subjectvitiligo
dc.subjectpathogenesis
dc.subjectRL1-803
dc.subjectthiol
dc.subjectOriginal Article
dc.subjectDisease activity
dc.subjectDermatology
dc.subject.sdg3. Good health
dc.titlePlasma Thiol Levels are Associated with Disease Severity in Nonsegmental Vitiligo
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Gulsen Akoglu","name":null,"surname":null,"rank":1,"pid":null},{"fullName":"Salim Neselioglu","name":null,"surname":null,"rank":2,"pid":{"id":{"scheme":"orcid","value":"0000-0002-0974-5717"},"provenance":null}},{"fullName":"Eda Karaismailoglu","name":null,"surname":null,"rank":3,"pid":{"id":{"scheme":"orcid","value":"0000-0003-3085-7809"},"provenance":null}},{"fullName":"Akin Aktas","name":null,"surname":null,"rank":4,"pid":null},{"fullName":"Ozcan Erel","name":null,"surname":null,"rank":5,"pid":null}],"openAccessColor":"gold","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"vitiligo"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"FOS","value":"0302 clinical medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"pathogenesis"},"provenance":null},{"subject":{"scheme":"keyword","value":"RL1-803"},"provenance":null},{"subject":{"scheme":"keyword","value":"thiol"},"provenance":null},{"subject":{"scheme":"keyword","value":"Original Article"},"provenance":null},{"subject":{"scheme":"keyword","value":"Disease activity"},"provenance":null},{"subject":{"scheme":"keyword","value":"Dermatology"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null}],"mainTitle":"Plasma Thiol Levels are Associated with Disease Severity in Nonsegmental Vitiligo","subTitle":null,"descriptions":["<jats:sec> <jats:title>Background:</jats:title> <jats:p>Vitiligo is a depigmenting cutaneous disorder with complex pathogenesis. Thiol compounds are well-known organic structures that play a major role in melanogenesis.</jats:p> </jats:sec> <jats:sec> <jats:title>Aim:</jats:title> <jats:p>The aim of this study was to determine the association between plasma thiol level and disease severity in patients with nonsegmental vitiligo.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>A total of 73 patients with nonsegmental vitiligo (57 generalized and 16 localized type) and age- and sex-matched 69 healthy controls were enrolled in the study. Plasma levels of native thiols, disulfides, and total thiols were measured by a novel and automated assay. Disease severity of vitiligo was assessed with Vitiligo Area Scoring Index (VASI) score. The extent, stage, and spread of vitiligo of patients were evaluated according to the Vitiligo European Task Force (VETF) system.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>The native and total thiol levels of vitiligo patients were higher than those of healthy control group (<jats:italic toggle=\"yes\">P</jats:italic>≤0.001 and 0.001, respectively). The median VASI score of patients was 0.7 (0.02–28.30). Univariate analyses showed that plasma native thiol levels, VETF spread score, disease duration, and vitiligo type significantly correlated with VASI scores (<jats:italic toggle=\"yes\">r</jats:italic>=0.237, <jats:italic toggle=\"yes\">P</jats:italic>=0.043; <jats:italic toggle=\"yes\">r</jats:italic>=0.458, <jats:italic toggle=\"yes\">P</jats:italic>&lt;0.001; and <jats:italic toggle=\"yes\">P</jats:italic>&lt;0.001, respectively). Stepwise multivariate analysis revealed that disease duration (β=0.017; <jats:italic toggle=\"yes\">P</jats:italic>=0.005) and spread score (β=1.301; <jats:italic toggle=\"yes\">P</jats:italic>=0.001) were found statistically significant as independent factors on VASI score.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>Although plasma native thiol level significantly correlated with VASI scores of patients, it is not a predictive factor for vitiligo severity.</jats:p> </jats:sec>"],"publicationDate":"2018-07-01","publisher":"Ovid Technologies (Wolters Kluwer Health)","embargoEndDate":null,"sources":["Crossref","Indian J Dermatol","Indian Journal of Dermatology, Vol 63, Iss 4, Pp 323-327 (2018)"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Indian Journal of Dermatology","issnPrinted":"0019-5154","issnOnline":"1998-3611","issnLinking":null,"ep":"327","iss":null,"sp":"323","vol":"63","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::71058830aae6e28ff2796997c19ba64c","originalIds":["10.4103/ijd.ijd_586_17","50|doiboost____|71058830aae6e28ff2796997c19ba64c","od_______267::4f8a18bd0d1f5d8f302d5bb46c74a5d8","30078877","PMC6052756","50|od_______267::4f8a18bd0d1f5d8f302d5bb46c74a5d8","oai:pubmedcentral.nih.gov:6052756","50|doajarticles::93c30fc1464c2aeb9316390a2991a5b6","oai:doaj.org/article:f33f38d96e434a0b8daa105398c61c99","2819522329"],"pids":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"},{"scheme":"pmid","value":"30078877"},{"scheme":"pmc","value":"PMC6052756"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":6,"influence":2.7889e-9,"popularity":4.28696e-9,"impulse":5,"citationClass":"C5","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"}],"type":"Article","urls":["https://doi.org/10.4103/ijd.ijd_586_17"],"publicationDate":"2018-07-01","refereed":"peerReviewed"},{"pids":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"}],"license":"CC BY NC SA","type":"Article","urls":["https://doi.org/10.4103/ijd.ijd_586_17"],"refereed":"nonPeerReviewed"},{"pids":[{"scheme":"pmid","value":"30078877"},{"scheme":"pmc","value":"PMC6052756"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/30078877"],"refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"}],"license":"CC BY NC SA","type":"Other literature type","urls":["http://dx.doi.org/10.4103/ijd.IJD_586_17"],"publicationDate":"2018-01-01","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"}],"type":"Article","urls":["https://doaj.org/article/f33f38d96e434a0b8daa105398c61c99"],"publicationDate":"2018-01-01","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.4103/ijd.ijd_586_17"},{"scheme":"mag_id","value":"2819522329"}],"type":"Article","urls":["https://dx.doi.org/10.4103/ijd.ijd_586_17"],"refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar